Improved OS for Patients With HER2-Positive Uterine Serous Carcinoma Receiving Trastuzumab Plus Chemotherapy
It has been estimated that approximately 30% of patients with advanced uterine serous carcinoma have HER2-positive disease.
Society of Gynecologic Oncology (SGO)
No OS Benefit for Addition of Metformin to Platinum-Based Therapy in Advanced Endometrial Cancer
The insulin-lowering properties of metformin, along with its effects on synthetic metabolism, were some of the rationales for its use as a cancer therapy.
Further Support for Sentinel Lymph Node Biopsy in Early-Stage Vulvar Cancer
This analysis represents the largest reported series of patients with early-stage vulvar cancer characterized by a negative sentinel lymph node biopsy.
Dendritic Cell Vaccination in Ovarian Cancer May Induce Long-Lasting Antitumor Immunity
Median OS was significantly improved when dendritic cell vaccination therapy was added to standard second-line chemo in platinum-sensitive, relapsed ovarian cancer.
Improved Quality of Life After Concurrent Surgery for Endometrial Cancer and Incontinence
Concurrent surgery for cancer and stress urinary incontinence was associated with significantly improved QoL for women with early endometrial neoplasms and urinary stress incontinence.
TSR-042, a PD-1 Inhibitor, for Recurrent or Advanced Endometrial Cancer
According to researchers, responses to TSR-042 were seen in subgroups of patients with disease characterized as microsatellite instability (MSI)-high and MSI-low.
Atezolizumab Plus Bevacizumab in Advanced Cervical Cancer
Median PFS was only 2.9 months for women with advanced cervical cancer receiving the combination of atezolizumab plus bevacizumab.
Pembrolizumab Plus Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
A clinical benefit rate of 86% was observed in a phase 2 trial of pembrolizumab plus chemotherapy in patients with recurrent, platinum-resistant ovarian cancer.
Promising Early Results for Tisotumab Vedotin in Advanced Cervical Cancer
According to researchers, responses to tisotumab vedotin were seen in women with refractory advanced cervical cancer.
Adjuvant Chemotherapy Not Associated With Improved Survival in Stage I Uterine Leiomyosarcoma
According to researchers, older age and black race were independent predictors of poor OS in women with stage I uterine leiomyosarcoma.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in SGO 2019
Loading... 
Loading...